The global In Vitro Diagnostics (IVD) market size was valued at USD 59.40 billion in the year 2017. It is expected to expand at a CAGR of 6.6% over the forecast period. Rising prevalence of chronic diseases is anticipated to propel this growth. Rise in obesity, unhealthy dietary habits, sedentary lifestyle, and high consumption of tobacco and alcohol are some of the factors responsible for high incidence of cancer, diabetes, cardiovascular diseases, and other disorders.
According to the National Institute of Health (NIH), in 2017, it was estimated that approximately 23.5 million Americans were living with autoimmune diseases. The prevalence is expected to increase over the forecast period. Moreover, according to the American Cancer Society (ACS), in 2018, about 1.7 million new cancer cases are estimated to be reported and around 609,640 individuals are likely to die due to cancer.
Growing geriatric population, which is prone to diseases, needs regular diagnostic tests. This is one of the major factors driving the market growth. Furthermore, technological developments in terms of accuracy, portability, and cost-effectiveness are estimated to accelerate the demand for IVD devices. For instance, Agena Bioscience launched MassARRAY system incorporated with CHIP Prep Module in Europe in June 2017. The system was marketed as CE-IVD product under the Directive 98/79/EC.
In addition, rising demand for Point-of-Care (PoC) devices is expected to fuel the market growth. Introduction of enhanced technologies such as miniaturization of microfluidics, biochips, and nano-biotechnology are expected to boost the demand for PoC products. These enhancements have led to a rise in the access to point-of-care diagnostic tests and are expected to facilitate rapid and effective test results.
On the basis of product, the In Vitro Diagnostics (IVD) market is segmented into instruments, reagents, and software. Reagents held the dominant market share of 64.63% in 2017 due to high usage in IVD testing. Rise in R&D initiatives and demand for self-test and point-of-care products are some of the factors expected to boost growth of the over the forecast period.
On the other hand, the instrument segment is expected to expand at a lucrative CAGR of 6.19% during the forecast period. Introduction of portable instruments such as cobas 4800 developed by Roche Diagnostics and GeneXpert by Cepheid, is expected to drive the growth over the forecast period.
On the basis of technology, the market is categorized into immunology, hematology, clinical chemistry, molecular diagnostics, coagulation, microbiology, and others. In 2017, clinical chemistry dominated the global IVD market with a revenue of USD 20.42 billion attributed to huge demand for reagents and test strips for urinalysis. Moreover, molecular diagnostics is expected to witness the fastest growth over the forecast period. Automation is an emerging trend observed in clinical testing. Availability of easy-to-use portable devices enables self-testing, which is expected to fuel the market growth in near future.
On the basis of application, the IVD market is categorized into infectious disease, diabetes, cancer, cardiology, nephrology, autoimmune diseases, drug testing, and others. The infectious disease segment held the largest market share in 2017 due to high prevalence of pneumonia, tuberculosis, and HIV/AIDS. Oncology is expected to witness the fastest CAGR of 8.93% by 2025. Increasing demand for self-care devices and POC diagnostics for the treatment of chronic diseases can boost the growth in the forthcoming years.
On the basis of end use, the market is segmented into hospitals, laboratories, home care, and others. IVD services are used by hospitals and laboratories as well as directly by patients. Hospitals accounted for the largest market share of 46.01% in 2017, owing to high demand as a result of rise in hospitalization. Homecare segment, on the other hand, is expected to register the fastest CAGR of 8.48% over the forecast period.
North America held the largest market share of 46.44% in 2017. Favorable government regulations, high healthcare expenditure, and presence of key market players are the key factors responsible for the regional growth.
On the other hand, Asia Pacific is expected to witness the fastest growth over the forecast period. It is anticipated to expand at a CAGR of 8.01% over the forecast period. High unmet clinical needs, improving healthcare infrastructure, and high target population are anticipated to provide growth potential to key manufacturers in the region.
Some of the key players in the market for in vitro diagnostics are bioMerieux SA; F. Hoffmann-La Roche Ltd.; Becton, Dickinson and Company; Hologic, Inc. (Gen-Probe); Siemens Healthineers; Abbott; Alere; Danaher; Sysmex Corporation; Qiagen; and Cepheid.
Key players focus on strategies such as mergers and acquisitions, collaborations, and new product developments. In addition, they are aiming at expanding their businesses across developing regions to boost their market share. For instance, in August 2018, Sysmex Corporation and JVCKENWOOD Corporation agreed to jointly establish a new company Creative Nanosystems Corporation to develop and manufacture biodevices.
|
Attribute |
Details |
|
Base year for estimation |
2017 |
|
Actual estimates/Historical data |
2014 - 2017 |
|
Forecast period |
2018 - 2025 |
|
Market representation |
Revenue in USD Billion & CAGR from 2017 to 2025 |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America & MEA |
|
Country scope |
U.S., Canada, U.K., Germany, Japan, China, Brazil, Mexico, South Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
|
15% free customization scope(equivalent to 5 analyst working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global In Vitro Diagnostics (IVD) market report on the basis of product, technology, application, end use, and region:
Product Outlook (Revenue, USD Billion, 2014 - 2025)
Instruments
Reagents
Services
Technology Outlook (Revenue, USD Billion, 2014 - 2025)
Immunology
Hematology
Clinical chemistry
Molecular Diagnostics
Coagulation
Microbiology
Others
Application Outlook (Revenue, USD Billion, 2014 - 2025)
Infectious disease
Diabetes
Oncology
Cardiology
Nephrology
Autoimmune diseases
Drug testing
Others
End-use Outlook (Revenue, USD Billion, 2014 - 2025)
Hospital
Laboratory
Home care
Others
Regional Outlook (Revenue, USD Billion, 2014 - 2025)
North America
U.S.
Canada
Europe
Germany
U.K.
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
Middle East & Africa
South Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
